INSILICO (03696) released its financial report, adding over 10 collaborations and holding $393 million in cash.

INSILICO (03696) released its 2025 annual performance on March 29, 2026. The company went public on the main board of the Hong Kong Stock Exchange on December 30, 2025, raising the largest amount of funds in the biopharmaceutical IPO market for that year; by the end of 2025, the company had cash and bank balances totaling $393 million, with an annual revenue of $56.24 million. On the platform side, the company completed upgrades to the biological, chemical, and scientific sectors under Pharma.AI, and launched the target discovery benchmark TargetBench 1.0, the multimodal chemical base model Nach01, and the large model training framework MMAI Gym. In terms of research and development, the company nominated 6 preclinical drug candidates throughout the year and advanced 8 projects to clinical stages. In terms of R&D cooperation, more than 10 cooperation agreements were signed, totaling $1.3 billion in value; several projects also reached milestones and generated revenue.